Immunoprecise's full-service facility offers B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including G protein coupled receptors (GPCRs) and other multi-membrane spanning proteins.
The new facility means Immunoprecise can now do B-cell services in-house, which will greatly increases the profit margin of the services it offers.
The addition of the B-cell sorting facility completes the company's full service platform for the antibody discovery process of antibodies and is expected to be followed by the opening of a similar facility in Europe in the second half of 2018.
A B-cell is a type of white blood cell that is vital to the body's immune system.
"B-cell screening, sorting and sequencing capability provides enhanced technological capacity that substantially increases throughput and identification [of] therapeutically relevant antibodies," said Jennifer Bath, the president and chief executive officer of Immunoprecise (IPA).
"The industry has increasingly identified its needs to out-source its antibody discovery process to a single source provider who has the technical and technological capability for high throughput and higher probability of identifying therapeutically relevant antibodies," she added.
"We anticipate IPA's global footprint and antibody discovery industry leadership will enable the further growth and expansion of our platform," she declared.
Shares in Immunoprecise were up by a fifth at C$0.90.